Covid-19: AstraZeneca may expose vaccine trial participants to virus
Team Udayavani, May 29, 2020, 12:24 PM IST
AstraZeneca is developing a leading coronavirus vaccine with Oxford University and has started phase 2 and 3 trials of the vaccine.
Now, the chief executive says although it is too early to deliberately expose vaccine trial participants to the pathogen, it may become an option.
AstraZeneca is looking to recruit around 10,000 adults and children in Britain and a few of the participants will have to become infected in the course of their normal lives to achieve a reliable reading from the study over the next few months.
Pascal Soriot, CEO, AstraZeneca, said, “We are running against time. We are seeing already in Europe the disease is declining. Very soon the disease intensity will be low, and it will become difficult, so we have to move very quickly”
“If the disease gets to a very low level, maybe challenge studies will have to be considered. But we felt it’s too early today to do that”, he added
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
‘Leadership change more dangerous than COVID’
Coronavirus variants can evade antibodies by spreading via super-cells – new research
Covid-19: 42 children orphaned in Karnataka
Related Articles More
Work from home effect: Count of males seeking emotional counselling sees upward trend
Does a plant-based diet really help beat COVID-19?
Listening to music near bedtime can be disruptive to sleep: Study
No link between genetic risk factor and severe COVID among South Asians: Study
Biophore applies to DCGI for emergency-use approval for COVID-19 treatment drug
Sirsi: II PUC exams cancelled; student commits suicide
‘One stance for the world, another in India’: Jairam Ramesh on PM Modi’s ‘One Earth, One Health’ remark at G7 address
Selectors have got good back-ups for whatever side they pick for WTC final: Taylor
Undeterred by pandemic, Skoda Auto eyes going past all-time peak sales volume next year
Five of top-10 valued firms add more than Rs 1 lakh cr in mcap; TCS, Infosys lead gainers